280 related articles for article (PubMed ID: 29980530)
1.
Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.
Börcsök J; Sztupinszki Z; Bekele R; Gao SP; Diossy M; Samant AS; Dillon KM; Tisza V; Spisák S; Rusz O; Csabai I; Pappot H; Frazier ZJ; Konieczkowski DJ; Liu D; Vasani N; Rodrigues JA; Solit DB; Hoffman-Censits JH; Plimack ER; Rosenberg JE; Lazaro JB; Taplin ME; Iyer G; Brunak S; Lozsa R; Van Allen EM; Szüts D; Mouw KW; Szallasi Z
Clin Cancer Res; 2021 Apr; 27(7):2011-2022. PubMed ID: 33208343
[TBL] [Abstract][Full Text] [Related]
4. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Van Allen EM; Mouw KW; Kim P; Iyer G; Wagle N; Al-Ahmadie H; Zhu C; Ostrovnaya I; Kryukov GV; O'Connor KW; Sfakianos J; Garcia-Grossman I; Kim J; Guancial EA; Bambury R; Bahl S; Gupta N; Farlow D; Qu A; Signoretti S; Barletta JA; Reuter V; Boehm J; Lawrence M; Getz G; Kantoff P; Bochner BH; Choueiri TK; Bajorin DF; Solit DB; Gabriel S; D'Andrea A; Garraway LA; Rosenberg JE
Cancer Discov; 2014 Oct; 4(10):1140-53. PubMed ID: 25096233
[TBL] [Abstract][Full Text] [Related]
5. Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment.
Zhou Q; Wu H; Miao F; Cao Y; Liang L; Huang J; Qian Z
Anticancer Drugs; 2023 Oct; 34(9):1046-1057. PubMed ID: 37578814
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
[TBL] [Abstract][Full Text] [Related]
7. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
[TBL] [Abstract][Full Text] [Related]
8. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
Liu D; Plimack ER; Hoffman-Censits J; Garraway LA; Bellmunt J; Van Allen E; Rosenberg JE
JAMA Oncol; 2016 Aug; 2(8):1094-6. PubMed ID: 27310333
[No Abstract] [Full Text] [Related]
9. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J; Mouw KW; Polak P; Braunstein LZ; Kamburov A; Kwiatkowski DJ; Rosenberg JE; Van Allen EM; D'Andrea A; Getz G
Nat Genet; 2016 Jun; 48(6):600-606. PubMed ID: 27111033
[TBL] [Abstract][Full Text] [Related]
10. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
11. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
Gangawar R; Ahirwar D; Mandhani A; Mittal RD
Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.
Sakano S; Wada T; Matsumoto H; Sugiyama S; Inoue R; Eguchi S; Ito H; Ohmi C; Matsuyama H; Naito K
Br J Cancer; 2006 Sep; 95(5):561-70. PubMed ID: 16880786
[TBL] [Abstract][Full Text] [Related]
13. DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
Grivas P
Clin Cancer Res; 2019 Feb; 25(3):907-909. PubMed ID: 30455203
[TBL] [Abstract][Full Text] [Related]
14. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.
Zhang G; Guan Y; Zhao Y; van der Straaten T; Xiao S; Xue P; Zhu G; Liu Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Chem Biol Interact; 2017 Feb; 263():55-65. PubMed ID: 28027876
[TBL] [Abstract][Full Text] [Related]
15. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer.
Topka S; Steinsnyder Z; Ravichandran V; Tkachuk K; Kemel Y; Bandlamudi C; Winkel Madsen M; Furberg H; Ouerfelli O; Rudin CM; Iyer G; Lipkin SM; Mukherjee S; Solit DB; Berger MF; Bajorin DF; Rosenberg JE; Taylor BS; de Stanchina E; Vijai J; Offit K
Clin Cancer Res; 2021 Apr; 27(7):1997-2010. PubMed ID: 33199492
[TBL] [Abstract][Full Text] [Related]
16. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
[TBL] [Abstract][Full Text] [Related]
18. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
19. The ERCC2/XPD Lys751Gln polymorphism affects DNA repair of benzo[a]pyrene induced damage, tested in an in vitro model.
Xiao S; Cui S; Lu X; Guan Y; Li D; Liu Q; Cai Y; Jin C; Yang J; Wu S; van der Straaten T
Toxicol In Vitro; 2016 Aug; 34():300-308. PubMed ID: 27139774
[TBL] [Abstract][Full Text] [Related]
20. A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.
Xu D; Cao Q; Wang L; Wang J; Xu B; Attwood K; Wei L; Wu Y; Smith GJ; Katsuta E; Takabe K; Chatta G; Guru KA; Goodrich DW; Li QJ
Mol Cancer Ther; 2022 May; 21(5):786-798. PubMed ID: 35247903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]